{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Shadyab AH"],"funding":["NIA NIH HHS","NHLBI NIH HHS","WHI NIH HHS"],"pubmed_abstract":["No study has evaluated whether associations of plasma phosphorylated tau 217 (p-tau217) with mild cognitive impairment (MCI) or dementia vary by race or hormone therapy (HT) use. We examined 2,766 cognitively unimpaired women ≥65 years randomized to HT vs placebo with 25-year follow-up. P-tau217 was associated with incident MCI/dementia (hazard ratio [HR], 2.43; 95% CI, 2.18-2.71) and each individual outcome (MCI: HR, 1.94; 95% CI, 1.72-2.20; dementia: HR, 3.17; 95% CI, 2.79-3.61). Associations between p-tau217 and dementia were stronger for women randomized to estrogen plus progestin vs placebo (HR, 4.18; 95% CI, 3.41-5.13 vs HR, 3.07; 95% CI, 2.41-3.91, respectively; <i>P</i> interaction=0.044) but did not vary for estrogen alone vs placebo. The combination of p-tau217 and age performed similarly in White and Black women (AUC=72.0% and 70.4%, respectively). Findings show the value of plasma p-tau217 for prediction of MCI and dementia up to 25 years in advance in older women."],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2025.10.30.25339146"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12636631"],"repository":["biostudies-literature"],"pubmed_title":["Plasma p-tau217 and incident mild cognitive impairment and dementia in older women: 25-year prospective study in The Women's Health Initiative Memory Study."],"pmcid":["PMC12636631"],"funding_grant_id":["U24 AG082930","R01 AG079149","75N92021D00001","75N92021D00002","75N92021D00003","75N92021D00004","75N92021D00005","R01 HL105065","U19 AG078109","RF1 AG069052","R01 AG075884","RF1 AG079397","RF1 AG077386","K99 AG082863"],"pubmed_authors":["Mielke MM","Reiner AP","Manson JE","Nguyen S","Li D","LaCroix AZ","McEvoy LK","Nievergelt CM","Maihofer AX","Ferrucci L","Casanova R","Shadyab AH","Ngo L","Resnick SM","Libermann TA","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"Plasma p-tau217 and incident mild cognitive impairment and dementia in older women: 25-year prospective study in The Women's Health Initiative Memory Study.","description":"No study has evaluated whether associations of plasma phosphorylated tau 217 (p-tau217) with mild cognitive impairment (MCI) or dementia vary by race or hormone therapy (HT) use. We examined 2,766 cognitively unimpaired women ≥65 years randomized to HT vs placebo with 25-year follow-up. P-tau217 was associated with incident MCI/dementia (hazard ratio [HR], 2.43; 95% CI, 2.18-2.71) and each individual outcome (MCI: HR, 1.94; 95% CI, 1.72-2.20; dementia: HR, 3.17; 95% CI, 2.79-3.61). Associations between p-tau217 and dementia were stronger for women randomized to estrogen plus progestin vs placebo (HR, 4.18; 95% CI, 3.41-5.13 vs HR, 3.07; 95% CI, 2.41-3.91, respectively; <i>P</i> interaction=0.044) but did not vary for estrogen alone vs placebo. The combination of p-tau217 and age performed similarly in White and Black women (AUC=72.0% and 70.4%, respectively). Findings show the value of plasma p-tau217 for prediction of MCI and dementia up to 25 years in advance in older women.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-06-03T03:16:38.277Z","creation":"2026-06-03T03:08:52.422Z"},"accession":"S-EPMC12636631","cross_references":{"pubmed":["41282951"],"doi":["10.1101/2025.10.30.25339146"]}}